CCSS treatment data is available to independent researchers through the CCSS review process. For additional information please contact the study at ccss@stjude.org.

I. Chemotherapy Summary Data

Table 1. Exposure to Specific Chemotherapeutic Agents by Cancer Diagnosis Among the Participants With Complete Abstraction of Medical Records (n = 12,455)*

		Diagnosis			
Agent	Participants N (%)	Leukemia N (%)	CNS N (%)	HD N (%)	NHL N (%)
All cases	12455 (100)	4215 (100)	1642 (100)	1685 (100)	908 (100)
Adenine Arabinoside	133 (1)	74 (2)	4 (< 1)	34 (2)	10 (1)
5-Azacytidine	179 (1)	177 (4)	0	0	2 (< 1)
AZQ	18 (< 1)	8 (< 1)	7 (< 1)	1 (< 1)	1 (< 1)
Bleomycin	754 (6)	5 (< 1)	8 (< 1)	373 (22)	56 (6)
Busulfan	46 (< 1)	38 (1)	0	4 (< 1)	1 (< 1)
Carboplatin	73 (1)	4 (< 1)	36 (2)	2 (< 1)	0
Carmustine (BCNU)	509 (4)	191 (5)	43 (3)	52 (3)	186 (20)
Chlorambucil	77 (1)	1 (< 1)	0	50 (3)	6 (1)
Cisplatin	729 (6)	8 (< 1)	165 (10)	21 (1)	14 (2)
Cyclocytidine Hydrochloride	17 (< 1)	14 (< 1)	1 (< 1)	0	0
Cyclophosphamide-PO	1005 (8)	412 (10)	14 (1)	20 (1)	46 (5)
Cyclophosphamide-IV	4972 (40)	2024 (48)	110 (7)	372 (22)	761 (84)
Cytarabine-IV/IM	2265 (18)	1820 (43)	97 (6)	36 (2)	280 (31)
Cytarabine-IT	1786 (14)	1528 (36)	6 (< 1)	2 (< 1)	201 (22)
Cytarabine-SQ	513 (4)	448 (11)	0	3 (< 1)	62 (7)
Dacarbazine (DTIC)	614 (5)	3 (< 1)	39 (2)	275 (16)	4 (< 1)
Dactinomycin	2492 (20)	66 (2)	39 (2)	4 (< 1)	23 (3)
Daunorubicin	1674 (13)	1403 (33)	1 (< 1)	0	260 (29)
Dexamethasone	1015 (8)	587 (14)	128 (8)	56 (3)	73 (8)
Doxorubicin	4031 (32)	1309 (31)	16 (1)	427 (25)	287 (32)
Etoposide (VP16)-PO	38 (< 1)	12 (< 1)	7 (< 1)	8 (< 1)	1 (< 1)
Etoposide (VP16)-IV	825 (7)	491 (12)	52 (3)	54 (3)	41 (5)
Fludarabine phosphate	4 (< 1)	3 (< 1)	0	0	0
Fluorouracil (5-FU)	70 (1)	4 (< 1)	14 (1)	3 (< 1)	2 (< 1)
Homoharringtonine	1 (< 1)	1 (< 1)	0	0	0
Hydroxyurea	510 (4)	186 (4)	124 (8)	1 (< 1)	184 (20)
Idarubicin	10 (< 1)	8 (< 1)	1 (< 1)	0	0
Ifosfamide	184 (1)	26 (1)	15 (1)	7 (< 1)	5 (1)
L-Asparaginase	3885 (31)	3591 (85)	3 (< 1)	0	291 (32)
Lomustine (CCNU)	501 (4)	16 (< 1)	279 (17)	168 (10)	32 (4)
m-AMSA	41 (< 1)	38 (1)	0	1 (< 1)	0
Mechlorethamine (N. Mustard)	792 (6)	7 (< 1)	44 (3)	658 (39)	21 (2)
Melphalan	135 (1)	4 (< 1)	3 (< 1)	40 (2)	1 (< 1)
Mercaptopurine (6-MP)	3908 (31)	3634 (86)	7 (< 1)	2 (< 1)	262 (29)
Methotrexate-PO	3448 (28)	3048 (72)	10 (1)	8 (< 1)	371 (41)
Methotrexate-IV	2700 (22)	1684 (40)	21 (1)	21 (1)	378 (42)
Methotrexate-IM	475 (4)	435 (10)	0	0	33 (4)
Methotrexate-IT	4536 (36)	3768 (89)	28 (2)	2 (< 1)	678 (75)
Myeleran	14 (< 1)	13 (< 1)	0	1 (< 1)	0
Pentostatin (Deoxycoformicin)	10 (< 1)	8 (< 1)	0	1 (< 1)	0
Plicamycin (Mithramycin)	5 (< 1)	3 (< 1)	1 (< 1)	0	0
Prednisone	5793 (47)	3920 (93)	164 (10)	862 (51)	788 (87)
Procarbazine	1289 (10)	2 (< 1)	223 (14)	1040 (62)	16 (2)
Teniposide (VM-26)	627 (5)	467 (11)	12 (1)	4 (< 1)	43 (5)
Thioguanine	1168 (9)	909 (22)	30 (2)	3 (< 1)	225 (25)
Thiotepa	66 (1)	15 (< 1)	6 (< 1)	35 (2)	2 (< 1)
Tretinoin (ATRA)	6 (< 1)	3 (< 1)	1 (< 1)	1 (< 1)	0
Vinblastine	588 (5)	24 (1)	4 (< 1)	509 (30)	23 (3)
Vincristine	8906 (72)	4028 (96)	385 (23)	933 (55)	820 (90)

Table 2. Exposure to Specific Chemotherapeutic Agents by Cancer Diagnosis among the Participants With Complete Abstraction of Medical Records (n = 12,455)*

	Diagnosis			
Agent	Kidney N (%)	Neuroblastoma N (%)	Soft tissue sarcoma N (%)	Bone cancer N (%)
All cases	1068 (100)	823 (100)	1079 (100)	1035 (100)
Adenine Arabinoside	3 (< 1)	1 (< 1)	5 (< 1)	2 (< 1)
5-Azacytidine	0 (< 1)	0	0	0
AZQ	1 (< 1)	0	0	0
Bleomycin	2 (< 1)	3 (< 1)	48 (4)	259 (25)
Busulfan	0	2 (< 1)	0	1 (< 1)
Carboplatin	5 (< 1)	8 (1)	4 (< 1)	14 (1)
Camustine (BCNU)	0	1 (< 1)	14 (1)	22 (2)
Chlorambucil	0	1 (< 1)	11 (1)	8 (1)
Cisplatin	20 (2)	109 (13)	109 (10)	283 (27)
Cyclocytidine Hydrochloride	0	0	2 (< 1)	0
Cyclophosphamide-PO	5 (< 1)	220 (27)	187 (17)	101 (10)
Cyclophosphamide-IV	90 (8)	351 (43)	603 (56)	661 (64)
Cytarabine-IV/IM	1 (< 1)	16 (2)	8 (1)	7 (1)
Cytarabine-IT	1 (< 1)	1 (< 1)	43 (4)	4 (< 1)
Cytarabine-SQ	0	0	0	0
Decarbazine (DTIC)	5 (< 1)	163 (20)	87 (8)	38 (4)
Dactinomycin	1044 (98)	13 (2)	768 (71)	535 (52)
Daunorubicin	1 (< 1)	4 (< 1)	3 (< 1)	2 (< 1)
Dexamethasone	7 (1)	19 (2)	48 (4)	97 (9)
Doxorubicin	446 (42)	224 (27)	471 (44)	851 (82)
Etoposide (VP16)-PO	1 (< 1)	3 (< 1)	2 (< 1)	4 (< 1)
Etoposide (VP16)-IV	31 (3)	18 (2)	79 (7)	59 (6)
Fludarabine phosphate	0	0	1 (< 1)	0
Fluorouracil (5-FU)	6 (1)	8 (1)	10 (1)	23 (2)
Homoharringtonine	0	0	0	0
Hydroxyurea	0	11 (1)	3 (< 1)	1 (< 1)
Idarubicin	0	0	1 (< 1)	0
Ifosfamide	19 (2)	7 (1)	43 (4)	62 (6)
L-Asparaginase	0	0	0	0
Lomustine (CCNU)	0	1 (< 1)	1 (< 1)	4 (< 1)
m-AMSA	1 (< 1)	0	1 (< 1)	0
Mechlorethamine (N. Mustard)	1 (< 1)	36 (4)	15 (1)	10 (1)
Melphalan	0	33 (4)	8 (1)	46 (4)
Mercaptopurine (6-MP)	0	0	3 (< 1)	0
Methotrexate-PO	0	0	4 (< 1)	7 (1)
Methotrexate-IV	0	6 (1)	60 (6)	530 (51)
Methotrexate-IM	0	0	2 (< 1)	5 (< 1)
Methotrexate-IT	2 (< 1)	5 (1)	45 (4)	8 (1)
Myeleran	0	0	0	0
Pentostatin (Deoxycoformicin)	1 (< 1)	0	0	0
Plicamycin (Mithramycin)	0	0	1 (< 1)	0
Prednisone	7 (1)	14 (2)	21 (2)	17 (2)
Procarbazine	0	6 (1)	1 (< 1)	1 (< 1)
Teniposide (VM-26)	5 (< 1)	85 (10)	8 (1)	3 (< 1)
Thioguanine	1 (< 1)	0	0	0
Thiotepa	2 (<1)	1 (< 1)	1 (< 1)	4 (< 1)
Tretinoin (ATRA)	0	1 (< 1)	0	0
Vinblastine	9 (1)	7 (1)	6 (1)	6 (1)
Vincristine	977 (91)	301 (37)	789 (73)	673 (65)

*Percentile distributions are not provided for idarubicin and myeleran, which had fewer than 30 cases exposed.

Reference: Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, Li FP, Meadows AT, Mulvihill JJ, Neglia JP, Nesbit ME, Packer RJ, Potter JD, Sklar CA, Smith MA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. Study Design and Cohort Characteristics of the Childhood Cancer Survivor Study: A Multi-Institutional Collaborative Project. Med Pediatr Oncol 38:229-39, 2002.

II. Radiotherapy Summary Data

CHILDHOOD CANCER SURVIVOR STUDY (CCSS)
RADIOTHERAPY*: ANATOMIC REGIONS WITH ONE OR MORE FIELDS 6/08/05

ROWS SUM TO MORE THAN 100%. SOME PATIENTS RECEIVED TREATMENT TO MULTIPLE REGIONS.

FIRST MALIGNANT NEOPLASM	# of Pts with XRT	Sites Treated																					
		Brain		Head (not brain)		Cranio-Spinal **		Neck		Chest		Spine		Abdomen		Pelvis		Limb		TBI		Region Unknown	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Leukemia	2916	2662	91.3%	77	2.6%	442	15.2%	69	2.4%	92	3.2%	443	15.2%	76	2.6%	371	12.7%	26	.9%	238	8.2%	56	1.9%
CNS	1160	1090	94.0%	70	6.0%	414	35.7%	63	5.4%	26	2.2%	426	36.7%	24	2.1%	26	2.2%	3	.3%	1	.1%	32	2.8%
Hodgkin	1576	13	.8%	189	12.0%	1	.1%	1477	93.7%	1428	90.6%	1	.1%	986	62.6%	609	38.6%	34	2.2%	4	.3%	30	1.9%
Non-Hodgkin Lymphoma	638	181	28.4%	150	23.5%	39	6.1%	239	37.5%	263	41.2%	41	6.4%	152	23.8%	160	25.1%	48	7.5%	17	2.7%	13	2.0%
Kidney Tumors	689	4	.6%	1	.1%			16	2.3%	262	38.0%			669	97.1%	340	49.3%	3	.4%			8	1.2%
Neuroblastoma	409	41	10.0%	35	8.6%	11	2.7%	70	17.1%	170	41.6%	14	3.4%	214	52.3%	114	27.9%	10	2.4%	16	3.9%	7	1.7%
Soft-Tissue Tumors	689	63	9.1%	270	39.2%	6	.9%	119	17.3%	122	17.7%	7	1.0%	84	12.2%	190	27.6%	129	18.7%	1	.1%	15	2.2%
Bone Tumors	386	30	7.8%	19	4.9%	5	1.3%	23	6.0%	167	43.3%	5	1.3%	47	12.2%	95	24.6%	185	47.9%	3	.8%	9	2.3%
Total	8463	4084	48.3%	811	9.6%	918	10.8%	2076	24.5%	2530	29.9%	937	11.1%	2252	26.6%	1905	22.5%	438	5.2%	280	3.3%	170	2.0%

*Includes radiotherapy at any time.

**Cranio-Spinal added as a category for patients who were treated to the brain and spine. Brain and spine may not have been treated at the same time or to the same dose. Patients with cranio-spinal treatments also are counted in the "brain" and "spine" category.

PERCENT OF PATIENTS TREATED WITH RADIATION THERAPY